Search
for
Sort by
Research 121–150 of 140
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Dermatological Indications: Alopecia Areata
- Non-Scarring Alopecia in Females: A Comprehensive Review
- Aim to alleviate alopecia areata with newly available agents
- Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Advances in the mechanism and new therapies of alopecia areata
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- An Updated in the Management of Alopecia Areata
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Recent advances in the genetics of alopecia areata
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Targeted immunotherapy for hair regrowth and regeneration
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- A phase 2a trial of brepocitinib for cicatricial alopecia
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- A review of Janus kinase inhibitor use in scarring alopecia
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials